TopBP1 Inhibitors

TopBP1 inhibitors represent a collection of compounds strategically designed to modulate the activity of TopBP1, a key protein involved in DNA replication and the DNA damage response. Among the selected inhibitors, NU6027, a CDK inhibitor, can influence TopBP1 through regulation of cyclin-dependent kinase activity, impacting cell cycle progression and DNA replication. VE-821 and AZD6738, both ATR inhibitors, modulate ATR signaling, thereby influencing TopBP1 through alterations in the DNA damage response pathway. SCH 900776 and BAY 1895344, CHK1 inhibitors, affect CHK1 kinase activity, impacting TopBP1 through the regulation of the DNA damage response and cell cycle checkpoints.

Other inhibitors, such as VX-970, AZ20, and UCN-01, target ATR, PKC, and CHK2, respectively, impacting TopBP1 through their regulatory effects on the DNA damage response, cell cycle progression, and DNA replication. CGP 74514A, a CHK2 inhibitor, and SB 218078, a CDK2 inhibitor, can also influence TopBP1 through their modulation of key kinases involved in DNA replication and cell cycle regulation. VX-680 (Tozasertib), an Aurora kinase inhibitor, represents another avenue for impacting TopBP1 by regulating the activity of Aurora kinases involved in cell cycle progression and DNA replication. In conclusion, the diverse class of TopBP1 inhibitors presented here provides researchers with a range of compounds to selectively modulate TopBP1 and investigate its role in crucial cellular processes associated with DNA replication and the DNA damage response. These inhibitors serve as valuable tools for unraveling the intricate regulatory networks governed by TopBP1 and its implications in cellular physiology and pathology.